WHO ICTRP trial
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose…
PACTR202211579014330 · Pan African Clinical Trials Registry (PACTR) · Recruiting
Key facts
| Trial ID | PACTR202211579014330 |
|---|---|
| Public title | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) |
| Scientific title | A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION IN PARTICIPANTS WITH EARLY OR LOCALLY ADVANCED/ INFLAMMATORY HER2-POSITIVE BREAST… |
| Primary sponsor | Hoffmann La Roche |
| Registry | Pan African Clinical Trials Registry (PACTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase-3 |
| Countries | Kenya;Kenya |
| Conditions | Cancer;Cancer |
| Interventions | Arm A ;Arm B;Arm C;Arm D |
| Registration date | Oct 26, 2022 |
| Target size | 330 |
| Registry page | pactr.samrc.ac.za |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: